ResearchMoz

China Diagnostic Reagent Industry Report, 2012-2014

Research In China
Published Date » 2013-01-04
No. Of Pages » 86
   
 Chinas diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in Chinas medical care investment and per capita health care spending, the Chinas diagnostic reagent market has a promising prospect.  
   
 In vitro diagnostic reagents account for more than 90.0% of the output of Chinas diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.  
   
 At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in Chinas diagnostic...
Table of Content

1. Overview of Diagnostic Reagent Industry
1.1 Definition
1.2 Classification

2. China Diagnostic Reagent Industry

2.1 Overview
2.2 Market Structure
2.3 Import and Export
2.3.1 Import
2.3.2 Export
2.4 Competitive Landscape
2.4.1 Biochemical Diagnostic Reagents
2.4.2 Immune Diagnostic Reagents
2.4.3 Molecular Diagnostic Reagents
2.4.4 Integrated In Vitro Diagnostic Reagents
2.5 Profitability
2.6 Entry Barriers
2.6.1 Technical Barriers
2.6.2 Quality and Brand Barriers
2.6.3 Marketing Channel Barriers
2.6.4 Market Access Barriers

3. Development Environment of China Diagnostic Reagent Industry
3.1 Policy Environment
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Industries
3.2.1 Industrial Chain
3.2.2 Upstream
3.2.3 Downstream

4. Development Forecast of China Diagnostic Reagent Industry
4.1 Overall Forecast
4.1.1 Market Demand Drivers
4.1.2 Market Scale Forecast
4.2 Development Trends of Diagnostic Reagent Industry
4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream
4.2.2 Industry Concentration Will Increase
4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win

5. Major Chinese Diagnostic Reagent Enterprises

5.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R & D and Investment
5.1.6 Customers
5.1.7 Diagnostic Reagent Business
5.1.8 Forecast and Prospect
5.2 Da An Gene Co., Ltd.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R & D and Investment
5.2.6 Diagnostic Reagent Business
5.2.7 Forecast and Prospect
5.3 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R & D and Investment
5.3.6 Diagnostic Reagent Business
5.3.7 Forecast and Prospect
5.4 BioSino Bio-technology and Science Inc.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 R & D and Investment
5.4.5 Forecast and Prospect
5.5 Beijing Kinghawk Pharmaceutical Co., Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 Diagnostic Reagent Business
5.5.6 Forecast and Prospect
5.6 Livzon Pharmaceutical Group Inc.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Diagnostic Reagent Business
5.6.6 Forecast and Prospect
5.7 Beijing Leadman Biochemistry Co., Ltd.
5.7.1 Profile
5.7.2 Operation
5.7.3 Revenue Structure
5.7.4 Gross Margin
5.7.5 R & D and Investment
5.7.6 Customers
5.7.7 Diagnostic Reagent Business
5.7.8 Forecast and Prospect
5.8 Acon Biotech (Hangzhou) Co., Ltd.
5.8.1 Profile
5.8.2 Operation
5.8.3 Development
5.9 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.9.3 Development
5.10 Shanghai Rongsheng Biotech Co., Ltd. (Rsbio)
5.10.1 Profile
5.10.2 Operation
5.10.3 Development
5.11 Shenzhen PG Biotech Co., Ltd.
5.11.1 Profile
5.11.2 Operation
5.12 Shanghai Upper Bio-Tech Pharma Co., Ltd.
5.12.1 Profile
5.12.2 Operation
5.12.3 Development
5.13 Inverness Medical (Shanghai) Co., Ltd.
5.13.1 Profile
5.13.2 Operation
5.14 Blue Cross Bio-Medical (Beijing) Co., Ltd.
5.14.1 Profile
5.14.2 Operation
5.14.3 Development
5.15 Beijing North Institute of Biological Technology (BNIBT)
5.15.1 Profile
5.15.2 Operation
5.15.3 Development

List of Tables

NA

List of Figures

NA

Upcoming Reports:

Poland: market of machines for plastic working
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the machines for plastic working market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the machines for plastic working market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Endocrinology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
The human endocrine system comprises of a number of glands such as pituitary, thyroid, parathyroid, pancreas, pineal, thymus, parathyroid and gonads. These glands secrete hormones into the blood which are responsible for metabolism, growth, sexual development and other body functions. Endocrinology drugs are used to treat diseases related with insufficient hormones supply and dysfunctional glands. Various diseases related with endocrine system are Addison’s diseases, Cushing’s syndrome, Diabetes, Goiter, acromegaly, gigantism, osteomalacia, hypertension, hyperlipidemia,...
Greece: nitrogen market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the nitrogen market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the nitrogen market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Blackstone Invests $800 Million in Asian Oil-Based Energy Company
Jul 31, 2014  
Blackstone Energy Partners announced to invest $800 million in an Asian based energy company that is led by former industry executives.  Blackstone is popularly considered a part of the world’s largest administrator of alternatives to financial stocks and bonds. New York-based managing director, Angelo Acconcia of Blackstone Energy Partners said in an interview that Tamarind...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...